Sleep Trial to Prevent Alzheimer's Disease
University of Minnesota · with Good Ventures, Merck Sharp & Dohme LLC · NCT04629547
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 65+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Phase 2
- Target enrollment
- 120
- US sites recruiting
- 1
- Study start
- May 25, 2022
- Record last updated
- July 13, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The purpose of this study is to determine if treatment with the sleep aid suvorexant can decrease the rate of amyloid-β (Aβ) accumulation in the brain.
Being studied: Suvorexant 20 mg; Placebo
Conditions: Sleep; Alzheimer Disease
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Male or female.
- Any race or ethnicity.
- Participants must be age ≥65 years and able to sign informed consent.
- Global Clinical Dementia Rating (CDR) 0.
- Willing and able to undergo study procedures.
Exclusion Criteria
- History of reported symptoms suggestive of restless legs syndrome, narcolepsy or other central disorder of hypersomnolence, or parasomnia
- STOP-Bang score >6 for participants without PAP
- Untreated OSA with AHI ≥15 on home sleep test
- Treated sleep apnea with PAP non-compliance
- PAP compliance is defined as >= 4 hours per night >70% of the nights
- Plasma A-beta and tau test with a plasma p-tau 217% ≤ 1.19
- Stroke.
- Chronic kidney disease defined as patients with markers of kidney damage or eGFR of \< 45 ml/min/1.73m2.
- Hepatic impairment defined as AST and/or ALT > 2x upper limit of normal (normal limits AST: 11-47 IU/L, ALT: 6-53 IU/L).
- HIV/AIDS.
- History of substance abuse or alcohol abuse in the proceeding 6 months.
- Regular alcohol consumption 3 or more days a week over the last 6 months. Regular alcohol consumption is defined as having more than 2 alcoholic beverages within 3 hours of bedtime. Participants that agree to reduce alcohol consumption during the study may not be excluded.
- History of presence of any clinically significant medical condition, behavioral or psychiatric disorder, or surgical history based on medical record or participant report that could affect the safety of the participant or interfere with study assessments or in the judgement of the Principal-Investigator (PI) if participant is not a good candidate.
- Has any medical condition that, in the PI's opinion, could increase risk to the participant, limit the participant's ability to tolerate the research procedures, or interfere with the collection/analysis of the data. Potential medical conditions that will be exclusionary at the PI's discretion:
- Cardiovascular disease requiring medication except for controlled hypertension.
- Pulmonary disease.
- Type I diabetes.
- Neurologic or psychiatric disorder requiring medication.
- Tobacco use.
- Use of sedating medications.
- Use of medications that interact with suvorexant (if cannot be discontinued)
- Abnormal safety labs
- History of current suicidal ideations.
- Currently pregnant or breast-feeding.
- In the opinion of the PI, the participant should be excluded due to an abnormal physical examination.
- Must not have participated in any clinical trial involving a study drug or device within the 30-days prior to study enrollment.
- Must not participate in another drug or device study prior to the end of this study participation.
Exclusion criteria for optional lumbar punctures
-• Contraindication to lumbar puncture (anticoagulants; bleeding disorder; allergy to lidocaine or disinfectant; prior central nervous system or lower back surgery).
Recruiting US locations
Washington University School of Medicine
St Louis, MO 63110
Site contact: Cristina Toedebusch, BS · 314-747-0646 · toedebuschc@wustl.edu
Study contacts (from the official record)
- Cristina Toedebusch, BS · 3147470646 · toedebuschc@wustl.edu
- Chloe Meehan, MA · 3142730878 · cmeehan@wustl.edu
Similar studies in Missouri
All sleep studies in Missouri →- RecruitingHealthy volunteersEarly Phase 1
Light Therapy for Obsessive-compulsive Disorder (OCD)
Washington University School of Medicine
- Location
- St Louis, MO
- Eligibility basics
- Ages 17–35
- Recruiting
Evaluation of the F&P Mask, US, 2026
Fisher and Paykel Healthcare
- Location
- St Louis, MO
- Eligibility basics
- Ages 22+
- RecruitingPhase 2
A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)
Takeda
- Location
- St Louis, MO + 24 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Eli Lilly and Company
- Location
- St Louis, MO + 22 other US sites
- Eligibility basics
- Ages 18+